Pharmadrug Inc.
PHRX
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 92.59% | -77.12% | |||
| Depreciation & Amortization | 0.00% | 3.41% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.48% | -55.25% | |||
| Operating Income | -34.48% | 55.25% | |||
| Income Before Tax | -3.26% | 24.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.26% | 24.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -18.18% | -25.42% | |||
| Net Income | -6.67% | 24.79% | |||
| EBIT | -34.48% | 55.25% | |||
| EBITDA | -92.59% | 77.12% | |||
| EPS Basic | 0.00% | 16.67% | |||
| Normalized Basic EPS | 0.00% | 25.00% | |||
| EPS Diluted | 0.00% | 16.67% | |||
| Normalized Diluted EPS | 0.00% | 25.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.43% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||